News Search Results
Jun 25, 2025, 04:10 ET Medical Ceramics Market to Reach $29.93 Billion by 2032, Growing at a CAGR of 6.2% from 2025, Says Meticulous Research®
sophisticated competitive ecosystem comprising established medical device manufacturers, specialized ceramic technology companies, and innovative biotechnology firms. This diverse landscape fosters rapid technological advancement and breakthrough medical applications. Industry leaders are implementing
More news about: Meticulous Market Research Pvt. Ltd.
Jun 25, 2025, 03:00 ET Blue Earth Therapeutics: SNMMI Presentation of Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial
Bracco family of companies. With proven management expertise across the spectrum of radiopharmaceutical and oncology drug development, as well as biotechnology start–up experience, the Company aims to innovate and improve upon current technologies and rapidly advance new targeted therapies for serious diseases.
More news about: Blue Earth Therapeutics LTD
Jun 24, 2025, 16:12 ET Indivior Appoints Tony Kingsley to the Board of Directors
delivering life-transforming treatments for opioid use disorder." Mr. Kingsley currently serves as CEO and Director of Stablix, Inc., a biotechnology company pioneering deubiquitination therapeutics as novel modality. Prior to joining Stablix, Mr. Kingsley was President and CEO of Scholar Rock,
More news about: Indivior PLC
Jun 24, 2025, 15:06 ET Breakthrough T1D Joins Diabetes Leaders at the American Diabetes Association 85th Scientific Sessions to Highlight Research Advancements
goes back decades.Sana Biotechnology
More news about: Breakthrough T1D, Formerly JDRF
Jun 24, 2025, 14:45 ET Hemab Therapeutics Presents Positive Clinical and Preclinical Data Across Bleeding Disorder Pipeline at ISTH 2025 Congress
Mass., June 24, 2025 /PRNewswire/ -- Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today announced clinical and preclinical
More news about: Hemab Therapeutics
Jun 24, 2025, 12:08 ET Ovarian Cancer Drugs Market Size expected to reach US$ 4.23 billion by 2031 | The Insight Partners
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact
More news about: The Insight Partners
Jun 24, 2025, 11:20 ET Electrotherapy Systems Market Size to Surpass USD 9.42 Billion by 2031, exhibiting a CAGR of 8.1% | The Insight Partners
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact
More news about: The Insight Partners
Jun 24, 2025, 11:00 ET Pulmonary Drug Delivery System Market Size to Worth USD 73.14 Billion by 2031 | The Insight Partners
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact
More news about: The Insight Partners
Jun 24, 2025, 10:45 ET Mangiferin Market to Surge from USD 225 Million to USD 384.5 Million by 2032 - Meticulous Research®
https://www.meticulousresearch.com/view-pricing/1453 Key Players in Mangiferin Market The mangiferin market features competition among established ingredient suppliers, biotechnology companies, and specialty chemical manufacturers. Leading players include Chemcopia Ingredients Pvt Ltd (India),
More news about: Meticulous Market Research Pvt. Ltd.
Jun 24, 2025, 10:30 ET Label-free Detection Market to Accelerate Growth from USD 2.64 Billion to USD 4.48 Billion by 2032 - Meticulous Research®
Rising Pharmaceutical Innovation, AI Integration, and Point-of-Care Testing Applications Drive 9.8% CAGR Growth Across Healthcare and Biotechnology Sectors Worldwide REDDING, Calif.,
More news about: Meticulous Market Research Pvt. Ltd.
Jun 24, 2025, 09:00 ET BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress
Prescribing Information for additional Important Safety Information. About BioMarin BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The
More news about: BioMarin Pharmaceutical Inc.
Jun 24, 2025, 08:00 ET Avant Technologies Creating New Company for Expansion of Diabetes Program
("Avant" or the "Company"), an emerging technology company developing healthcare solutions using both artificial intelligence (AI) and developments in biotechnology, today announced that it will create a new company to house either a joint venture, partnership, or acquisition as it further expands its interests
More news about: Avant Technologies Inc.
Jun 24, 2025, 07:30 ET Mark Hensley joins RBL LLC as a senior adviser
drive substantial growth in the biotechnology sector. Hensley holds a Bachelor of Science in biology with a minor in chemistry from the University of North Texas, and his expertise spans a wide range of disciplines within the biotechnology and life sciences industries.
More news about: RBL LLC
Jun 24, 2025, 07:30 ET REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis
June 24, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced statistically significant data from the 16-week induction period of
More news about: Nektar Therapeutics
Jun 24, 2025, 07:00 ET Pharmactive's Saffron Extract Helps Lighten the Mood
mood swings." About Pharmactive Pharmactive Biotech Products is a Madrid-based pioneering biotechnology company that develops and manufactures differentiated natural ingredients supported by science, such as damiana extract, pure saffron extract, and
More news about: Pharmactive Biotech Products, S.L.U.
Jun 24, 2025, 07:00 ET Ascidian Therapeutics Appoints Dr. Murray A. Abramson as Chief Development Officer and Establishes Ophthalmology Clinical Advisory Board to Advance ACDN-01 for Treatment of Stargardt Disease
Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced the appointment of Murray A. Abramson,
More news about: Ascidian Therapeutics
Jun 24, 2025, 06:30 ET Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today
More news about: Immunic, Inc.
Jun 24, 2025, 06:00 ET Abcentra Announces Appointment of Dr. Peter Libby as a Board Member as it Enters Orticumab's Phase 2b Trial (FORTIFY)
ANGELES, June 24, 2025 /PRNewswire/ -- Abcentra LLC (Abcentra), a clinical stage biotechnology company specializing in coronary artery disease, today announced the appointment of Dr. Peter Libby, MD as a Board
More news about: Abcentra
Jun 23, 2025, 17:00 ET TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals
novel technologies to overcome resistance to cancer immunotherapy, today announced with Kineta, Inc. (OTC Pink:KANT) ("Kineta"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, that TuHURA stockholders approved
More news about: TuHURA Biosciences, Inc.
Jun 23, 2025, 16:30 ET Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025
June 23, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review top-line
More news about: Nektar Therapeutics
Jun 23, 2025, 16:15 ET New Data Signals IVD Growth in a Shifting Market Amid Tariff Uncertainty
Kalorama Information, part of Science and Medicine Group, has been a leading publisher of market research in medical markets, including the biotechnology, diagnostics, medical device, and pharmaceutical industries for more than 30 years. Our comprehensive, timely, quality research and innovative approach
More news about: Kalorama Information
Jun 23, 2025, 14:31 ET RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Jun 23, 2025, 11:37 ET Lilly declares third-quarter 2025 dividend
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Jun 23, 2025, 11:00 ET Atrogi announces Cell paper highlighting transformative potential of muscle-targeted therapy in metabolic disease
STOCKHOLM, June 23, 2025 /PRNewswire/ -- Atrogi AB, a clinical-stage biotechnology company pioneering muscle-targeted therapies, today announces the publication of a landmark study in the prestigious scientific journal Cell,
More news about: Atrogi AB
Jun 23, 2025, 10:47 ET TOBY Urine Test completes participation in 2025 Mayo Clinic and ASU Alliance for Health Care MedTech Accelerator
BOSTON, June 23, 2025 /PRNewswire/ -- TOBY, Inc., a biotechnology company focusing on improving early cancer screening, today announced its completion of its participation in the Mayo Clinic and Arizona
More news about: TOBY, Inc.